Literature DB >> 21104216

[Porphyrias].

U Stölzel1, T Stauch, M O Doss.   

Abstract

Porphyrias are metabolic disorders of the heme biosynthesis. Clinically, they can be differentiated into acute and non-acute porphyrias. The symptomatic phase of acute hepatic porphyrias is characterized by overproduction of neurotoxic porphyrin precursors and porphyrins. Acute intermittent porphyria, Variegate porphyria, Hereditary coproporphyria and Doss porphyria belong to this group of metabolic disorders. The clinical presentation of the acute hepatic porphyria syndrome includes abdominal, psychiatric, neurological and cardiovascular symptoms. The diagnosis is based on a tenfold increased urinary excretion of porphobilinogen (apart from Doss porphyria). Besides symptomatic therapy with non-porphyrinogenic drugs, electrolyte compensation and intensive monitoring, intravenous administration of glucose and heme arginate is established for treatment. Among the non-acute types like Porphyria cutanea tarda, Erythropoietic protoporphyria and Congenital erythropoietic porphyria, the accumulated porphyrins cause photosensitivity of the skin up to severe liver damage. The location of the deficient enzyme within the heme biosynthesic pathway determines the pattern of the accumulated porphyrins. Besides light protection, there are different therapies depending on the type of non-acute porphyria. Ultimately, liver transplantation may be considered in therapy-resistant cases of acute hepatic porphyrias and bone marrow transplantation in severe cases of erythropoietic porphyrias.

Entities:  

Mesh:

Year:  2010        PMID: 21104216     DOI: 10.1007/s00108-010-2751-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

1.  C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.

Authors:  Sharon D Whatley; Sarah Ducamp; Laurent Gouya; Bernard Grandchamp; Carole Beaumont; Michael N Badminton; George H Elder; S Alexander Holme; Alexander V Anstey; Michelle Parker; Anne V Corrigall; Peter N Meissner; Richard J Hift; Joanne T Marsden; Yun Ma; Giorgina Mieli-Vergani; Jean-Charles Deybach; Hervé Puy
Journal:  Am J Hum Genet       Date:  2008-09-04       Impact factor: 11.025

2.  Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda.

Authors:  Ulrich Stölzel; Erich Köstler; Detlef Schuppan; Matthias Richter; Uwe Wollina; Manfred O Doss; Christian Wittekind; Andrea Tannapfel
Journal:  Arch Dermatol       Date:  2003-03

3.  Treatment of porphyria cutanea tarda by phlebotomy.

Authors:  H Ippen
Journal:  Semin Hematol       Date:  1977-04       Impact factor: 3.851

Review 4.  Hepatic porphyrias: pathobiochemical, diagnostic, and therapeutic implications.

Authors:  M O Doss
Journal:  Prog Liver Dis       Date:  1982

5.  Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha.

Authors:  Christoph Handschin; Jiandie Lin; James Rhee; Anne-Kathrin Peyer; Sherry Chin; Pei-Hsuan Wu; Urs A Meyer; Bruce M Spiegelman
Journal:  Cell       Date:  2005-08-26       Impact factor: 41.582

Review 6.  Liver transplantation for porphyria: who, when, and how?

Authors:  Avnish Kumar Seth; Michael N Badminton; Darius Mirza; Scott Russell; Elwyn Elias
Journal:  Liver Transpl       Date:  2007-09       Impact factor: 5.799

7.  Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.

Authors:  S Fargion; A Piperno; M D Cappellini; M Sampietro; A L Fracanzani; R Romano; R Caldarelli; R Marcelli; L Vecchi; G Fiorelli
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

8.  The "glucose effect" in acute hepatic porphyrias and in experimental porphyria.

Authors:  M Doss; F Verspohl
Journal:  Klin Wochenschr       Date:  1981-07-01

9.  Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?

Authors:  U Wollina; E Köstler; A Koch; H Riedel; U Stölzel
Journal:  Int J Dermatol       Date:  2009-11       Impact factor: 2.736

10.  Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin.

Authors:  H L Bonkowsky; D P Tschudy; A Collins; J Doherty; I Bossenmaier; R Cardinal; C J Watson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

View more
  1 in total

1.  [Altered orientation and aggressiveness in an 89-year-old woman].

Authors:  M Kowar; A H Jacobs
Journal:  Internist (Berl)       Date:  2018-01       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.